Financial News

Johnson & Johnson 4Q Results

Innovative Medicine sales were $14.3 billion in the quarter, up 4%.

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

4Q Revenues: $22.5 billion (+5%)

4Q Earnings: $3.4 billion (-17%)

FY Revenues: $88.8 billion (+4%)

FY Earnings: $14.1 billion (+6%)

Comments: Innovative Medicine sales were $14.3 billion in the quarter, up 4%, and $57.0 billion for the year, up 4%. Growth in the quarter was driven primarily by DARZALEX up 21% to $3.1 billion, ERLEADA up 21% to $784 million, TREMFYA in Immunology, up 4%to $949 million, and SPRAVATO in Neuroscience, up 45% to $297 million. Growth was partially offset by STELARA in Immunology, down 15% to $2.3 billion. Remeicade sales were down 17% to $359 million, in the quarter. Infectious diseases sales were down 9% to $774 million. INVEGA SUSTENNA sales were $1.06 billion, up 5%. IMBRUVICA sales were down 7% to $731 million. XARELTO sales were up 29% to $676 million.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters